Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | JAK2 | O60674 | 6/20 | 0.35 |
| ▸ | NTRK1 | P04629 | 6/20 | 0.35 |
| ▸ | GCK | P35557 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 4/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1958740 | 1.00 | ALDH1A1 (0.35) | ALDH1A1JAK2NTRK1GCKLMNA | |
| SCHEMBL1962506 | 0.90 | NR1H3 (0.33) | ALDH1A1GCK | |
| SCHEMBL1962508 | 0.90 | NR1H3 (0.33) | ALDH1A1GCK | |
| SCHEMBL1961207 | 0.89 | ALDH1A1 (0.36) | ALDH1A1GCKLMNAHTTTP53 | |
| SCHEMBL1961209 | 0.89 | ALDH1A1 (0.36) | ALDH1A1GCKLMNAHTTTP53 | |
| SCHEMBL1960904 | 0.88 | GCK (0.40) | ALDH1A1GCKLMNAHTTHPGD | |
| SCHEMBL1960900 | 0.88 | GCK (0.40) | ALDH1A1GCKLMNAHTTHPGD | |
| SCHEMBL1962772 | 0.87 | PTGS2 (0.37) | ALDH1A1GCK | |
| SCHEMBL1962775 | 0.87 | PTGS2 (0.37) | ALDH1A1GCK | |
| SCHEMBL1962026 | 0.83 | FKBP1A (0.32) | ALDH1A1GCKLMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2513103-A1 | AZAINDOLE GLUCOKINASE ACTIVATORS | F. Hoffmann-La Roche AG (CH) | 2012-10-24 | — | — | EP | disclosed |
| US-8222416-B2 | Azaindole glucokinase activators | HOFFMANN-LA ROCHE INC. (US) | 2012-07-17 | — | — | US | disclosed |
| WO-2011073117-A1 | AZAINDOLE GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-23 | — | — | WO | disclosed |
| US-20110144105-A1 | AZAINDOLE GLUCOKINASE ACTIVATORS | BERTHEL STEVEN JOSEPH | 2011-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144105-A1 | AZAINDOLE GLUCOKINASE ACTIVATORS | GCK, GCKR, GALK1 | ALDH1A1 769/4885JAK2 1756/4885NTRK1 3641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.